Table 2.
Immunosuppressive therapy and Ig anti-SARS-CoV-2 post-vaccination serological status (N = 121).
| Immunosuppressive Therapy | |||
|---|---|---|---|
| Seropositivity | p-Value | ||
| Double | 59 (48.7%) | 42 (71%) | 0.044 |
| Triple | 62 (51.3%) | 20 (32%) | |
|
Tacrolimus-
containing regimens |
90 (74.3%) | 44 (49%) | 0.275 * |
| Mycophenolate-containing regimens | 59 (48.7%) | 16 (27%) | 0.039 * |
|
Steroid-
containing regimens |
105 (86.8%) | 56 (53%) | 0.450 * |
|
Everolimus-
containing regimens |
17 (14%) | 9 (53%) | 0.530 * |
| Cyclosporine-containing regimens | 23 (19%) | 12 (52%) | 0.285 * |
|
Sirolimus-
containing regimens |
7 (5.8%) | 6 (86%) | 0.320 * |
|
Azathioprine-
containig regimens |
3 (2.5%) | 1 (33%) | 0.254 * |
* vs. other treatments.